[New therapeutic strategies in HIV infection-immune reconstitution and virus suppression].
BACKGROUND
In the last years, highly active antiretroviral therapy has decreased AIDS-associated mortality of patients dramatically. Due to this prolonged lifetime, the emergence of resistance against antiretroviral therapy has increased. Additionally, cross-resistance within the classes of nucleoside reverse transcriptase inhibitors (NRTI), non-nucleoside reverse transcriptase inhibitors (NNRTI), and protease inhibitors (PI) complicates HIV therapy. Development of new classes of therapeutic agents can help avoiding cross-resistance. Fuzeon, the first agent in the new class of fusion inhibitors, should be combined with as many effective antiretroviral agents as possible.


METHODS
The course of a 106-week therapy in a patient infected with a multiresistant virus is described.


CONCLUSIONS
Fusion inhibitor Fuzeon represents a new option for patients having multiple resistance against HAART.
Herzmann
Christian
C
EPIMED GmbH, c/o Vivantes Auguste-Viktoria-Klinikum, Berlin.
Düesberg
Uta
U
Arastéh
Keikawus
K
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000276:immunology; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D018432:Drug Resistance, Multiple; D024882:Drug Resistance, Viral; D000077560:Enfuvirtide; D015700:HIV Envelope Protein gp41 / Q000627:therapeutic use*; D023581:HIV Fusion Inhibitors / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D007108:Immune Tolerance / Q000187:drug effects; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000627:therapeutic use*
D019380:Anti-HIV Agents; D015700:HIV Envelope Protein gp41; D023581:HIV Fusion Inhibitors; D010446:Peptide Fragments; D000077560:Enfuvirtide